A 42-year-old woman with a 10-year history of hereditary spherocytosis presents with jaundice and splenomegaly. She has undergone splenectomy 5 years ago with good clinical response. Regarding the laboratory findings and management of hereditary spherocytosis, all of the following statements are correct EXCEPT:

Question

Accepted Answer

A. Splenectomy is curative and completely eliminates the hemolytic process. ## Hereditary Spherocytosis: Diagnosis and Management

### Understanding the Correct Answer

**Key Point:** **Splenectomy is NOT curative in hereditary spherocytosis.** While splenectomy provides dramatic clinical improvement (70–80% reduction in hemolysis), it does **NOT eliminate the hemolytic process**. The underlying RBC membrane defect persists; splenectomy merely removes the primary site of RBC destruction.

**High-Yield:** After splenectomy, patients still have:
- Persistent spherocytes on blood smear
- Positive osmotic fragility test
- Continued (though reduced) hemolysis
- Risk of extravascular hemolysis in other tissues (liver, bone marrow)

### Pathophysiology: Why Splenectomy Is Not Curative

```mermaid
flowchart TD
  A[Hereditary Spherocytosis]:::outcome --> B[RBC membrane protein defect]:::outcome
  B --> C[Loss of RBC deformability]:::action
  C --> D[Splenic trapping & phagocytosis]:::action
  D --> E[Hemolysis in spleen]:::urgent
  E --> F{Splenectomy?}:::decision
  F -->|Yes| G[Hemolysis reduced but NOT eliminated]:::action
  F -->|No| H[Progressive hemolysis]:::urgent
  G --> I[Extrasplenic hemolysis continues]:::outcome
```

### Diagnostic Tests for Hereditary Spherocytosis

| Test | Finding in HS | Clinical Use |
|------|---------------|---------------|
| **Blood smear** | Spherocytes (dense, no central pallor) | Initial screening |
| **Osmotic fragility test** | **Increased** (RBCs lyse at higher osmotic pressure) | Confirms membrane defect |
| **EMA/Flow cytometry** | Decreased EMA binding | Gold standard (replaces osmotic fragility) |
| **Autohemolysis test** | Increased (>10% at 48 hrs) | Detects membrane defect |
| **Genetic testing** | Mutations in spectrin, ankyrin, band 3, protein 4.2 | Confirmatory but not routine |

**Clinical Pearl:** EMA (eosin-5-maleimide) binding test is now the **preferred diagnostic test** because it is more specific, sensitive, and objective than osmotic fragility, which can be affected by other conditions (e.g., AIHA).

### Why Other Options Are Correct

1. **Osmotic fragility is increased** — spherocytes have reduced surface-area-to-volume ratio and lyse at higher osmotic pressures than normal RBCs — correct.
2. **EMA binding test is the gold standard** — it has replaced osmotic fragility as the diagnostic test of choice — correct.
3. **Spherocytes result from membrane protein mutations** — defects in spectrin, ankyrin, band 3, or protein 4.2 cause loss of RBC deformability — correct.

### Clinical Outcomes After Splenectomy

**Before splenectomy:**
- Hemoglobin: 7–10 g/dL
- Reticulocyte count: 10–20%
- Bilirubin: elevated

**After splenectomy:**
- Hemoglobin: 10–13 g/dL (improvement but not normalization)
- Reticulocyte count: 3–5% (reduced but still elevated)
- Bilirubin: reduced but may remain mildly elevated
- **Spherocytes persist on blood smear**
- **Osmotic fragility remains abnormal**

Answer

B. Osmotic fragility test is increased (RBCs lyse at higher osmotic pressure than normal)

Answer

C. Spherocytes result from mutations in genes encoding red cell membrane proteins like spectrin and ankyrin

Answer

D. Eosin-5-maleimide (EMA) binding test has replaced osmotic fragility as the diagnostic gold standard

Explanation

Hereditary Spherocytosis: Diagnosis and Management

Understanding the Correct Answer

Pathophysiology: Why Splenectomy Is Not Curative

Diagnostic Tests for Hereditary Spherocytosis

Why Other Options Are Correct

Clinical Outcomes After Splenectomy

Practice similar questions

Join our NEET PG community

Test	Finding in HS	Clinical Use
Blood smear	Spherocytes (dense, no central pallor)	Initial screening
Osmotic fragility test	Increased (RBCs lyse at higher osmotic pressure)	Confirms membrane defect
EMA/Flow cytometry	Decreased EMA binding	Gold standard (replaces osmotic fragility)
Autohemolysis test	Increased (>10% at 48 hrs)	Detects membrane defect
Genetic testing	Mutations in spectrin, ankyrin, band 3, protein 4.2	Confirmatory but not routine